Perrigo’s Global Expectations Counter Slower U.S. OTC Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
The private labeler hopes its international expansion will help mitigate the impact of the return of major branded OTCs from J&J and Novartis to the market.
You may also be interested in...
Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth
Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.
Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth
Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.
FTC's Substantiation Expectations In Consumer Health Claim Guidance Aren’t ‘Out Of Nowhere'
“Choosing which claims to make,” an advertiser “affects the amount of substantiation required. A structure function claim, supports digestive health, may require a different level of substantiation than if you choose to make the claim prevents diarrhea,” says FTC attorney Christine DeLorme.